Tavia E. Evans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tavia E. Evans has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Natalia Vilor-Tejedor
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
10 shared publications - Hieab H. H. Adams
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
8 shared publications - Juan Domingo Gispert
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation
7 shared publications - Patricia Genius
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation
7 shared publications Albert Rodrigo
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona 08005, Spain; Department of Rheumatology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain
4 shared publicationsArcadi Navarro
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona 08005, Spain; Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain; Institute of Evolutionary Biology (CSIC-UPF), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain
4 shared publications
Latest Publications
- 29 July 2026
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 22 (10) , 662
Reply to ‘Low-field MRI for equitable epilepsy diagnosis in resource-limited settings’
- 29 July 2026
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 22 (10) , 662
Reply to ‘Low-field MRI for equitable epilepsy diagnosis in resource-limited settings’
- 1 May 2026
- Published by Springer Nature
- p. 76-83
Super-Resolution of Ultra-Low-Field MRI Using a GAN-Based Visual Transformer Network
- 1 May 2026
- Published by Springer Nature
- p. 76-83
Super-Resolution of Ultra-Low-Field MRI Using a GAN-Based Visual Transformer Network
- 7 April 2026
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 22 (6) , 337-350
The potential of low-field MRI for global dementia care
With elderly populations increasing in many countries, rates of Alzheimer disease and related dementias (ADRD) are expected to rise worldwide in the coming years. Low-income and middle-income countries, where barriers to health care are most pronounced and research representation is limited, are predicted to experience the greatest increases in ADRD prevalence. Access to advanced diagnostic and research tools, such as neuroimaging, is severely restricted in these regions, but low-field MRI is emerging as a promising, accessible alternative to conventional imaging. By reducing infrastructure, cost and siting requirements, low-field MRI offers a potential pathway to expand access to dementia-relevant imaging beyond specialized centres. In this article, we summarize key structural imaging biomarkers in ADRD and review the current literature supporting the use of low-field MRI in the ADRD field. We highlight the utility of low-field MRI for the assessment of regional atrophy and cerebrovascular lesion burden and discuss emerging diffusion-based markers. We also consider challenges and future directions, offering insights to advance equitable access to diagnostic imaging, guide research priorities and support global implementation of low-field MRI in ADRD care and investigation.
- 7 April 2026
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 22 (6) , 337-350
The potential of low-field MRI for global dementia care
With elderly populations increasing in many countries, rates of Alzheimer disease and related dementias (ADRD) are expected to rise worldwide in the coming years. Low-income and middle-income countries, where barriers to health care are most pronounced and research representation is limited, are predicted to experience the greatest increases in ADRD prevalence. Access to advanced diagnostic and research tools, such as neuroimaging, is severely restricted in these regions, but low-field MRI is emerging as a promising, accessible alternative to conventional imaging. By reducing infrastructure, cost and siting requirements, low-field MRI offers a potential pathway to expand access to dementia-relevant imaging beyond specialized centres. In this article, we summarize key structural imaging biomarkers in ADRD and review the current literature supporting the use of low-field MRI in the ADRD field. We highlight the utility of low-field MRI for the assessment of regional atrophy and cerebrovascular lesion burden and discuss emerging diffusion-based markers. We also consider challenges and future directions, offering insights to advance equitable access to diagnostic imaging, guide research priorities and support global implementation of low-field MRI in ADRD care and investigation.
- Open Access
Multidomain determinants of perivascular spaces indicate early cerebrovascular vulnerability in individuals at risk of Alzheimer’s disease
Background: Perivascular spaces (PVS) are increasingly recognized as MRI-visible markers of cerebrovascular and glymphatic functions. However, the determinants of regional PVS burden in the preclinical stages of Alzheimer’s disease (AD) remain to be elucidated, particularly when considering the impact of sex and core AD biomarkers. Methods: We studied 1,199 cognitively unimpaired participants from the ALFA cohort, enriched for AD genetic risk and deeply phenotyped, including cerebrospinal fluid (CSF) biomarkers. PVS were automatically quantified in the basal ganglia, centrum semiovale, hippocampus, and midbrain on 3T MRI. Regional PVS counts were modeled using Poisson or negative binomial regression, accounting for demographics, cardiometabolic, lifestyle and genetic factors. Effect modification by sex and CSF amyloid/tau (AT) classification was examined. Results: Determinants of PVS burden showed marked regional specificity. In the centrum semiovale, PVS burden was associated with age, male-sex and cardiometabolic factors. In contrast, hippocampal and midbrain PVS were more closely related to AD biomarker status and to psychological or sleep-related measures. Pronounced sex differences were observed, with men exhibiting higher PVS burden in centrum semiovale, while women showed higher PVS counts in the hippocampus, midbrain and basal ganglia. Associations between vascular, lifestyle, and genetic factors and PVS burden were stronger in amyloid-positive individuals, particularly those with concurrent amyloid and tau pathology, suggesting increased perivascular vulnerability along the AD continuum. Genetic risk scores for metabolic and lipid-related traits contributed modestly and independently to regional PVS variation, with evidence of sex- and biomarker-specific effects. Conclusions: PVS burden reflects multidomain influences on cerebrovascular and clearance dysfunction in preclinical AD, with distinct regional, sex-specific, and biomarker-dependent patterns. These findings support PVS as an accessible MRI marker of early cerebrovascular vulnerability and highlight their potential relevance for risk stratification and precision prevention strategies before symptom onset.
Open AccessMultidomain determinants of perivascular spaces indicate early cerebrovascular vulnerability in individuals at risk of Alzheimer’s disease
Background: Perivascular spaces (PVS) are increasingly recognized as MRI-visible markers of cerebrovascular and glymphatic functions. However, the determinants of regional PVS burden in the preclinical stages of Alzheimer’s disease (AD) remain to be elucidated, particularly when considering the impact of sex and core AD biomarkers. Methods: We studied 1,199 cognitively unimpaired participants from the ALFA cohort, enriched for AD genetic risk and deeply phenotyped, including cerebrospinal fluid (CSF) biomarkers. PVS were automatically quantified in the basal ganglia, centrum semiovale, hippocampus, and midbrain on 3T MRI. Regional PVS counts were modeled using Poisson or negative binomial regression, accounting for demographics, cardiometabolic, lifestyle and genetic factors. Effect modification by sex and CSF amyloid/tau (AT) classification was examined. Results: Determinants of PVS burden showed marked regional specificity. In the centrum semiovale, PVS burden was associated with age, male-sex and cardiometabolic factors. In contrast, hippocampal and midbrain PVS were more closely related to AD biomarker status and to psychological or sleep-related measures. Pronounced sex differences were observed, with men exhibiting higher PVS burden in centrum semiovale, while women showed higher PVS counts in the hippocampus, midbrain and basal ganglia. Associations between vascular, lifestyle, and genetic factors and PVS burden were stronger in amyloid-positive individuals, particularly those with concurrent amyloid and tau pathology, suggesting increased perivascular vulnerability along the AD continuum. Genetic risk scores for metabolic and lipid-related traits contributed modestly and independently to regional PVS variation, with evidence of sex- and biomarker-specific effects. Conclusions: PVS burden reflects multidomain influences on cerebrovascular and clearance dysfunction in preclinical AD, with distinct regional, sex-specific, and biomarker-dependent patterns. These findings support PVS as an accessible MRI marker of early cerebrovascular vulnerability and highlight their potential relevance for risk stratification and precision prevention strategies before symptom onset.
- Open Access
- 7 November 2025
- Published by Brain Health Literacy Company Limited by Guarantee in Journal of Brain Health
- Vol. 1 (1)
Introducing the Journal of Brain Health: Mission Statement and Editorial Vision
The Journal of Brain Health is a peer-reviewed, interdisciplinary, open access journal advancing global brain health research with a focus on equity, inclusion, and scientific excellence. Founded by a group including Atlantic Fellows for Equity in Brain Health, the Journal aims to elevate the science of brain health by including underrepresented voices in research to promote access to credible, context-relevant science for all. We publish original research, perspectives, and commentary that reflect the transdisciplinary and global nature of brain health.
- 7 November 2025
- Published by Brain Health Literacy Company Limited by Guarantee in Journal of Brain Health
- Vol. 1 (1)
Open AccessIntroducing the Journal of Brain Health: Mission Statement and Editorial Vision
The Journal of Brain Health is a peer-reviewed, interdisciplinary, open access journal advancing global brain health research with a focus on equity, inclusion, and scientific excellence. Founded by a group including Atlantic Fellows for Equity in Brain Health, the Journal aims to elevate the science of brain health by including underrepresented voices in research to promote access to credible, context-relevant science for all. We publish original research, perspectives, and commentary that reflect the transdisciplinary and global nature of brain health.
- Open Access
- 11 October 2025
- Published by Elsevier in NeuroImage: Clinical
- Vol. 48, 103889
Genetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment
- 11 October 2025
- Published by Elsevier in NeuroImage: Clinical
- Vol. 48, 103889
Open AccessGenetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment
- 2 July 2025
- Published by Springer Nature
- p. 365-400
Genomics and Transcriptomics of Alzheimer Disease
- Open Access
Genetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment
The hippocampus, crucial in cognitive aging and Alzheimer’s disease (AD), shows early atrophy during disease progression. This study investigates 5-year trajectories of hippocampal volumes across AD stages, focusing on genetic predisposition to AD and their impact on hippocampal atrophy. Analyzing data from 1,051 participants in the ADNI, we found that higher genetic predisposition to AD accelerates hippocampal atrophy, particularly in individuals with mild cognitive impairment (MCI). Effects were primarily driven by cerebrospinal fluid protein quantitative trait loci of APOE. Excluding the APOE region from analyses negated these effects, underscoring its critical role. This stage-specific effect suggests that AD genetic factors, particularly the APOE region, exert their influence primarily before or during the transition to MCI, highlighting the hippocampus’s increased vulnerability during this period. These findings underscore the importance of targeting the MCI stage for early detection and intervention in AD. Further research is warranted to elucidate these dynamics and their potential clinical applications.
Open AccessGenetic drivers of hippocampal atrophy highlight the role of APOE functional variants and AD polygenicity in Mild Cognitive Impairment
The hippocampus, crucial in cognitive aging and Alzheimer’s disease (AD), shows early atrophy during disease progression. This study investigates 5-year trajectories of hippocampal volumes across AD stages, focusing on genetic predisposition to AD and their impact on hippocampal atrophy. Analyzing data from 1,051 participants in the ADNI, we found that higher genetic predisposition to AD accelerates hippocampal atrophy, particularly in individuals with mild cognitive impairment (MCI). Effects were primarily driven by cerebrospinal fluid protein quantitative trait loci of APOE. Excluding the APOE region from analyses negated these effects, underscoring its critical role. This stage-specific effect suggests that AD genetic factors, particularly the APOE region, exert their influence primarily before or during the transition to MCI, highlighting the hippocampus’s increased vulnerability during this period. These findings underscore the importance of targeting the MCI stage for early detection and intervention in AD. Further research is warranted to elucidate these dynamics and their potential clinical applications.
- Open Access
Shorter leukocyte telomere length is associated with distinct CSF biomarker dynamics across early AD stages in at-risk individuals
INTRODUCTION: Telomere length (TL) is a hallmark of biological aging. Shorter TL has been linked to an increased risk of Alzheimer’s disease (AD), but its role in AD pathophysiology remains unclear. This study investigates the relationship between TL, longitudinal cerebrospinal fluid (CSF) AD biomarkers, and brain structure in cognitively unimpaired (CU) individuals at risk for AD. METHODS: We analyzed data from 346 middle-aged CU ALFA+ participants, measuring leukocyte TL (LTL) by qPCR. AD-related CSF biomarkers were measured at baseline and after 3 years. Stratified analyses by APOE -e4 and amyloid-tau (AT) status were conducted. RESULTS: Shorter LTL was associated with higher astrocytic reactivity and synaptic dysfunction biomarkers, as well as thicker cortex in AD-vulnerable regions. Astrocytic biomarkers mediated the LTL-cortical thickness association. In APOE -e4 carriers and AT-positive individuals, shorter LTL linked to higher p-tau181 and neurodegeneration markers. CONCLUSION: These findings highlight telomere shortening as a potential contributor of early AD-related progression. Highlights: Shorter leukocyte telomere length (LTL) was associated with higher levels of cerebrospinal fluid (CSF) GFAP, CSF S100B and CSF α-synuclein, independently of amyloid and tau pathology. Shorter LTL was associated with higher baseline CSF NfL and t-tau levels in the A+T- and A+T+ groups, respectively. LTL association with brain structure was partially mediated by CSF biomarkers of astrocytic reactivity. Research in context: 1. Systematic review: Literature review was performed using traditional sources (e.g., PubMed). While the association between leukocyte telomere length (LTL) shortening and increased sporadic AD risk is well-documented, its role in AD pathogenesis remains unclear. These findings have been appropriately referenced. 2. Interpretation: In cognitively unimpaired adults at higher risk for AD, shorter LTL was associated with high AD-related cerebrospinal fluid (CSF) biomarkers, including p-tau181 and biomarkers of neurodegeneration, synaptic dysfunction, glial reactivity, and inflammation. These associations were either more pronounce or exclusively observed in APOE -e4 carriers and individuals with early AD pathology (measured by CSF Aβ42/40 and p-tau181). Furthermore, increased astrocytic reactivity mediated the relationship between LTL and brain structure integrity. 3. Future directions: Further research is needed to understand the role of peripheral aging in AD pathology. Investigating how peripheral immune aging influences brain homeostasis and AD progression could help identify early targets of neuroinflammation and neurodegeneration.
Open AccessShorter leukocyte telomere length is associated with distinct CSF biomarker dynamics across early AD stages in at-risk individuals
INTRODUCTION: Telomere length (TL) is a hallmark of biological aging. Shorter TL has been linked to an increased risk of Alzheimer’s disease (AD), but its role in AD pathophysiology remains unclear. This study investigates the relationship between TL, longitudinal cerebrospinal fluid (CSF) AD biomarkers, and brain structure in cognitively unimpaired (CU) individuals at risk for AD. METHODS: We analyzed data from 346 middle-aged CU ALFA+ participants, measuring leukocyte TL (LTL) by qPCR. AD-related CSF biomarkers were measured at baseline and after 3 years. Stratified analyses by APOE -e4 and amyloid-tau (AT) status were conducted. RESULTS: Shorter LTL was associated with higher astrocytic reactivity and synaptic dysfunction biomarkers, as well as thicker cortex in AD-vulnerable regions. Astrocytic biomarkers mediated the LTL-cortical thickness association. In APOE -e4 carriers and AT-positive individuals, shorter LTL linked to higher p-tau181 and neurodegeneration markers. CONCLUSION: These findings highlight telomere shortening as a potential contributor of early AD-related progression. Highlights: Shorter leukocyte telomere length (LTL) was associated with higher levels of cerebrospinal fluid (CSF) GFAP, CSF S100B and CSF α-synuclein, independently of amyloid and tau pathology. Shorter LTL was associated with higher baseline CSF NfL and t-tau levels in the A+T- and A+T+ groups, respectively. LTL association with brain structure was partially mediated by CSF biomarkers of astrocytic reactivity. Research in context: 1. Systematic review: Literature review was performed using traditional sources (e.g., PubMed). While the association between leukocyte telomere length (LTL) shortening and increased sporadic AD risk is well-documented, its role in AD pathogenesis remains unclear. These findings have been appropriately referenced. 2. Interpretation: In cognitively unimpaired adults at higher risk for AD, shorter LTL was associated with high AD-related cerebrospinal fluid (CSF) biomarkers, including p-tau181 and biomarkers of neurodegeneration, synaptic dysfunction, glial reactivity, and inflammation. These associations were either more pronounce or exclusively observed in APOE -e4 carriers and individuals with early AD pathology (measured by CSF Aβ42/40 and p-tau181). Furthermore, increased astrocytic reactivity mediated the relationship between LTL and brain structure integrity. 3. Future directions: Further research is needed to understand the role of peripheral aging in AD pathology. Investigating how peripheral immune aging influences brain homeostasis and AD progression could help identify early targets of neuroinflammation and neurodegeneration.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum
Background: Hippocampal atrophy is one of the most characteristic biomarkers of Alzheimer’s disease (AD), and its genetic basis, as well as that of its distinct subfields, is of current interest. However, hippocampal subfields have so far only been assessed largely unrelated to brain atrophy, and the majority of studies were focused on general population samples, explicitly excluding diagnosed patients. In this study, we evaluated whether hippocampal subfields trajectories are a suitable endophenotype to discern between neurodegenerative and aging genetic influences in the Alzheimer’s continuum.Method: The dataset includes AD patients (N = 113), mild cognitive impairment (N = 426), and control normal (CN) (N = 272) subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. Individuals were evaluated with 3T MRI at baseline and every 6 months for a total of 96 months. Hippocampal subfields were extracted using longitudinal processing within FreeSurfer(6.0). We used longitudinal mixed‐effect models with random intercept for individuals to investigated the association between hippocampal subfields volumetric changes and genetic predisposition to AD, Parkinson’s disease, frontotemporal dementia (neurodegeneration), as well as intrinsic and extrinsic epigenetic clock acceleration and telomere length (biological aging). Models were adjusted by age, sex, AD‐stage and total hippocampal volume. Disease status‐specific trajectories were also assessed.Result: Genetic predisposition to biological aging (driven by genetic predisposition to telomere length) was significantly associated with subfield changes in presubiculum (β = ‐11.2, p = 4.1e‐04), parasubiculum (β = ‐4.4, padj = 4.4e‐04), molecular layer (β = 5.9, padj = 2.0e‐04), dentate gyrus (DG) (β = 5.79, padj = 4.4e‐04), CA4 (β = 7.2, padj = 4.4e‐05), and HATA (β = ‐1.7, padj = 0.027). Genetic predisposition to neurodegeneration (driven by predisposition to AD) was associated with volumetric changes in CA3 (β = 4.4, p = 0.047). In stratified models, we observed significant volumetric changes due to genetic predisposition to neurodegeneration in controls (CA1, CA4, DG, parasubiculum, molecular layer). In MCI (subiculum regions and CA4) and AD (hippocampal fissure, molecular layer and DG), volumetric changes were mostly associated with genetic predisposition to biological aging processes.Conclusion: We showed differential genetic mechanisms associated with hippocampal subfield trajectories that were specific to Alzheimer’s disease stage. These results may help elucidate new biological mechanisms in the course of the disease as well as discern additional molecular mechanisms related to neurodegeneration and aging.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessDiscerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum
Background: Hippocampal atrophy is one of the most characteristic biomarkers of Alzheimer’s disease (AD), and its genetic basis, as well as that of its distinct subfields, is of current interest. However, hippocampal subfields have so far only been assessed largely unrelated to brain atrophy, and the majority of studies were focused on general population samples, explicitly excluding diagnosed patients. In this study, we evaluated whether hippocampal subfields trajectories are a suitable endophenotype to discern between neurodegenerative and aging genetic influences in the Alzheimer’s continuum.Method: The dataset includes AD patients (N = 113), mild cognitive impairment (N = 426), and control normal (CN) (N = 272) subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. Individuals were evaluated with 3T MRI at baseline and every 6 months for a total of 96 months. Hippocampal subfields were extracted using longitudinal processing within FreeSurfer(6.0). We used longitudinal mixed‐effect models with random intercept for individuals to investigated the association between hippocampal subfields volumetric changes and genetic predisposition to AD, Parkinson’s disease, frontotemporal dementia (neurodegeneration), as well as intrinsic and extrinsic epigenetic clock acceleration and telomere length (biological aging). Models were adjusted by age, sex, AD‐stage and total hippocampal volume. Disease status‐specific trajectories were also assessed.Result: Genetic predisposition to biological aging (driven by genetic predisposition to telomere length) was significantly associated with subfield changes in presubiculum (β = ‐11.2, p = 4.1e‐04), parasubiculum (β = ‐4.4, padj = 4.4e‐04), molecular layer (β = 5.9, padj = 2.0e‐04), dentate gyrus (DG) (β = 5.79, padj = 4.4e‐04), CA4 (β = 7.2, padj = 4.4e‐05), and HATA (β = ‐1.7, padj = 0.027). Genetic predisposition to neurodegeneration (driven by predisposition to AD) was associated with volumetric changes in CA3 (β = 4.4, p = 0.047). In stratified models, we observed significant volumetric changes due to genetic predisposition to neurodegeneration in controls (CA1, CA4, DG, parasubiculum, molecular layer). In MCI (subiculum regions and CA4) and AD (hippocampal fissure, molecular layer and DG), volumetric changes were mostly associated with genetic predisposition to biological aging processes.Conclusion: We showed differential genetic mechanisms associated with hippocampal subfield trajectories that were specific to Alzheimer’s disease stage. These results may help elucidate new biological mechanisms in the course of the disease as well as discern additional molecular mechanisms related to neurodegeneration and aging.